Monoclonal antibodies in the treatment of bronchial asthma

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


The article discusses different phenotypes of heterogeneous bronchial asthma (BA), methods of identification of patients with severe bronchial asthma, based on clinical characteristics, biological and genetic markers. Definition of phenotypes/ endotypes of BA contributes to better understanding of the nature of the disease and is feasible for development of an individual approach to therapy, because some types of BA may differ in resistance response to the standard treatment. The article gives an overview of modern research focused on the use of monoclonal antibodies in the treatment of BA. It discusses the algorithm of selection of patients with severe BA for prescribing of biological therapy.

Restricted Access

N I Ilina

NRC Institute of Immunology FMBA of Russia

O M Kurbacheva

NRC Institute of Immunology FMBA of Russia

Email: kurbacheva@gmail.com

  1. Global Strategy for Asthma Management and Prevention. Revised 2018. www.ginasthma.com.
  2. Chuchalin AG, Khaltaev N., Antonov N. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of COPD. 2014; 9: 963-974.
  3. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M. Severe Asthma. Lessons Learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J. Respir Crit Care Med. 2012; 185: 356-362. Published online 2012 Feb 15. doi: 10.1164/rccm.201107-1317PP
  4. Bousqet J., Mantzouranis E., Cruz AA, At-Khaled N., Baena-Cagnani CE, Bleecker ER et al. Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J. Allergy Clin Immunol. 2010; 126: 926-38.
  5. Белевский АС, Вишнева ЕА, Ильина Н.И. Наблюдательная программа «Общероссийский регистр пациентов с тяжелой бронхиальной астмой» (пилотный проект на примере Москвы). Практическая пульмонология. 2017; (1): 44-50
  6. Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J. Intern Med. 2016; 279: 192-204.
  7. Ненашева Н.М. Биологическая терапия бронхиальной астмы: настоящее и будущее. Consilium Medicum. 2016; 18 (11): 30-38.
  8. Wechsler M., Lehman E., Lazarus S. National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. beta-аdrenergic receptor polymorphisms and response to salmeterol. American Journal Respir Crit Care Medicine. 2006; 173: 519-526.
  9. Weaver C., Hatton R., Mangan P., Harrington L. IL-17 family cytokines and the expanding diversity of effector T. cell lineages. Annual Revy Immunology. 2007; 25: 821-852.
  10. Bullens D., Truyen E., Coteur L., Dilissen E., Hellings PW, Dupont LJ et al. IL-17 mRNA in sputum of asthmatic patients: linking T-cell driven inflammation and ranulocytic influx? Respir Res. 2006; 7: 135.
  11. Kawaguchi M., Takahashi D., Hizawa N., Suzuki S., Matsukura S., Kokubu F. et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wildtype IL-17F activity. J. Allergy Clin Immunol. 2006; 117: 795-801.
  12. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы 2016. www.pulmonology. ru
  13. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». IV изд. М.: Oригинал-макет. 2012: 161
  14. Peters SP, Jones SP, Haselkorn SP, Mink DR, Valacer DJ, Weiss ST Real-World Evaluation of Asthma Control and Treatment (REACT): Findings from a National Web-Based Survey. J. Allergy Clin Immunol. 2007; 119: 1454-1461.
  15. Hekking PP, Wener RR, Amelink M., Zwinderman AH, Bouvy ML, Bel EH. J. Allergy Clin Immunol. 2015; 135: 896-902.
  16. Курбачёва ОМ, Павлова К.С. Фенотипы и эндотипы бронхиальной астмы: от патогенеза и клинической картины к выбору терапии. Российский Аллергологический Журнал. 2013; (1): 15-24
  17. Stephenson L. Monoclonal Antibody Therapy for Asthma. Clin Pulm Med. 2017; 24: 250-257.
  18. International ERS/ATS guidelines on definition, evaluation and treatment ofsevere asthma. Eur Respir J. 2014; 43: 343-373.
  19. Инструкция по применению лекарственного препарата для медицинского применения Ксолар (ЛСР-000082 от 29.05.2007)
  20. Alhossan A., Lee CS, MacDonald K., Abraham I. «Real-life» Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. Allergy Clin Immunol Pract. 2017; 5: 1362-1370.
  21. Corren J., Kavati A., Ortiz B., Colby JA, Ruiz K., Maiese BA et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. Allergy Asthma Proc. 2017; 38: 250-263.
  22. Инструкция по применению препарата Нукала. Рег. № ЛП-004794
  23. Ortega HG, Yancey SW, Mayer B., Gunsoy NB, Keene ON, Bleecker ER et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4: 549-556.
  24. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral glucocorticoid-sparing effect of mepo-lizumab in eosinophilic asthma. NEJM. 2014; 371(13): 1189-1197. doi: 10.1056/NEJMoa1403291.
  25. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J., Nelsen LM et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial Lancet Respir Med. 2017; 5: 390-400. Claim present in the reference at: Pg. 397.
  26. GSK Protocol Document No.: 2015N243304_01, Study ID: 204471 (https://www.gsk-clinicalstudyregister.com/ study/204471?search=study&study_ids=204471#ps).
  27. Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics. 2013; 7: 7-11.
  28. Инструкция по медицинскому применению препарата Синкейро (реслизумаб)
  29. Castro M., Zangrilli J., Wechsler ME, Bateman ED, Brusselle GG, Bardin P. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015 3: 355-366.
  30. Murphy K., Jacobs J., Bjermer L. Long-term safety and efficacy of reslizumab in patients with inadequately controlled, moderate-to-severe asthma and elevated blood eosinophil counts: an open-label extension study. Presented at the American Thoracic Society (ATS) International Conference; 15-20 May 2015.
  31. Data on file (Clinical study report: a 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Reslizumab [3,0 mg/kg] in the reduction of clinical asthma exacerbations in patients [12-75 years of age] with eosinophilic asthma. Study C38072/3082). Summary 15.47. Horsham, PA: Teva Respiratory, LLC; January 2015].
  32. Cinqair prescribing information. Horsham, PA: Teva pharmaceuticals, LLC.
  33. Castro M., Mathur S., Hargreave F., Boulet LP, Xie F. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J. Respir Crit Care Med. 2011; 184: 1125-1132.
  34. Domingo C. Overlapping Effects of Monoclonal Antibodies for Severe Asthma. Drugs. 2017; 77: 1769-1787. DOI: 10.1007/ s40265-017-0810-5.

Views

Abstract - 35

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2018 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies